RANI Quote, Financials, Valuation and Earnings

Exelixis, Inc. has a net margin of -4223.26% compared to Rani Therapeutics Holdings, Inc.'s net margin of 32.38%. Rani Therapeutics Holdings, Inc.'s return on equity of -82920.89% beat Exelixis, Inc.'s return on equity of 31.26%.

Rani Therapeutics Holdings, Inc. has a consensus price target of $9.25, signalling upside risk potential of 560.71%. On the other hand Exelixis, Inc. has an analysts' consensus of $45.28 which suggests that it could fall by -2.08%. Given that Rani Therapeutics Holdings, Inc. has higher upside potential than Exelixis, Inc., analysts believe Rani Therapeutics Holdings, Inc. is more attractive than Exelixis, Inc..

Rani Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.

Rani Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rani Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.

Rani Therapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Rani Therapeutics Holdings, Inc.'s net income of -$7.9M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Rani Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 19.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rani Therapeutics Holdings, Inc. is 43.48x versus 5.78x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Disc Medicine, Inc. has a net margin of -4223.26% compared to Rani Therapeutics Holdings, Inc.'s net margin of --. Rani Therapeutics Holdings, Inc.'s return on equity of -82920.89% beat Disc Medicine, Inc.'s return on equity of -32.82%.

Rani Therapeutics Holdings, Inc. has a consensus price target of $9.25, signalling upside risk potential of 560.71%. On the other hand Disc Medicine, Inc. has an analysts' consensus of $121.67 which suggests that it could grow by 51.46%. Given that Rani Therapeutics Holdings, Inc. has higher upside potential than Disc Medicine, Inc., analysts believe Rani Therapeutics Holdings, Inc. is more attractive than Disc Medicine, Inc..

Rani Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Disc Medicine, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.406%.

Rani Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Disc Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rani Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Disc Medicine, Inc. pays out -- of its earnings as a dividend.

Rani Therapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Disc Medicine, Inc. quarterly revenues of --. Rani Therapeutics Holdings, Inc.'s net income of -$7.9M is higher than Disc Medicine, Inc.'s net income of -$62.3M. Notably, Rani Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Disc Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rani Therapeutics Holdings, Inc. is 43.48x versus -- for Disc Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -4223.26% compared to Rani Therapeutics Holdings, Inc.'s net margin of 31.72%. Rani Therapeutics Holdings, Inc.'s return on equity of -82920.89% beat Eli Lilly & Co.'s return on equity of 106.26%.

Rani Therapeutics Holdings, Inc. has a consensus price target of $9.25, signalling upside risk potential of 560.71%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.44%. Given that Rani Therapeutics Holdings, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Rani Therapeutics Holdings, Inc. is more attractive than Eli Lilly & Co..

Rani Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Rani Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Rani Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rani Therapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Rani Therapeutics Holdings, Inc.'s net income of -$7.9M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Rani Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rani Therapeutics Holdings, Inc. is 43.48x versus 16.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of -4223.26% compared to Rani Therapeutics Holdings, Inc.'s net margin of --. Rani Therapeutics Holdings, Inc.'s return on equity of -82920.89% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Rani Therapeutics Holdings, Inc. has a consensus price target of $9.25, signalling upside risk potential of 560.71%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $46.00 which suggests that it could grow by 75.37%. Given that Rani Therapeutics Holdings, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Rani Therapeutics Holdings, Inc. is more attractive than Olema Pharmaceuticals, Inc..

Rani Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.

Rani Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rani Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rani Therapeutics Holdings, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Rani Therapeutics Holdings, Inc.'s net income of -$7.9M is higher than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Rani Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rani Therapeutics Holdings, Inc. is 43.48x versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.